The cost, and that is confidential & was negotiated for all in all , 300 million doses, is slightly less than the $19.50 per photo the United States agreed to purchase a very first shipment of hundred million doses of the identical vaccine, in series with what Reuters reported in November.
The EU booklet dated Nov. 18 was circulated internally right after the EU announced its supply deal with Pfizer and its German partner BioNTech on Nov. eleven.
The EU drug regulator is actually expected to decide on Monday on approval for the Pfizer vaccine after the photo was authorised in a few countries, like Britain as well as the United States.
On Thursday Belgian declare secretary for the spending budget Eva De Bleeker printed on Twitter a table with costs Belgium would spend pharmaceutical companies for the COVID 19 vaccines of theirs. She retracted the content shortly after publishing.
In this table the Pfizer vaccine was suggested as costing Belgium 12 euros ($14.6) per dose, leading many to think this was the full cost agreed by the EU.
Other vaccines in the family table were furthermore shown with prices lower than prices disclosed by EU solutions.
“There is , naturally, a total fee and a price upon delivery,” an EU official involved in talks with vaccine creators told Reuters when made to clarify the difference between the EU and Belgian prices.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality needs, but pointed to what De Bleeker told the Belgian parliament last week. In that public hearing, De Beeker stated Belgium’s budgeted price tags were still partial.
Under EU advanced purchase deals for COVID-19 vaccines, the bloc agrees upfront payments with companies to secure doses before they’re approved. After approvals, EU governments can pay the rest to buy reserved doses.
The EU hasn’t revealed the upfront transaction agreed with Pfizer.
But, it said in October that it paid aproximatelly one billion euros found in downpayments to AstraZeneca, Sanofi and Johnson & Johnson for the shots of theirs, with an additional 1.45 billion euros budgeted for upfront payments to Pfizer BioNTech, Curevac and Moderna.
It’s since agreed source deals with all 6 organizations and it is negotiating a seventh arrangement with Novavax.